– USA, MA – Charles River Laboratories International, Inc. (NYSE: CRL) announced the nominations of Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves to join its Board as Independent Directors effective following the 2025 AGM on May 20, 2025.
Concurrently, existing directors Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman will not seek re-election at the end 2025 AGM. The board will consist of eleven directors, nine of whom will be independent.
About Steven Barg
Steven Barg is Global Head of Engagement at Elliott Investment Management L.P. and brings significant M&A and capital markets expertise, as well as public board experience in the CDMO/CRO space. Before joining Elliott in February of 2020, Mr. Barg spent 30 years in investment banking, most recently as a Participating Managing Director at Goldman Sachs. Mr. Barg established and led what became the firm’s Global Activism and Shareholder Advisory practice; founded and led the M&A Capital Markets practice; and ran Asian Equity Capital Markets in Hong Kong. In addition, Mr. Barg served on both the Asian and Global Equity Commitments Committees and was Global Head of Diversity for the Investment Banking Division. Before joining Goldman Sachs, Mr. Barg served as a Managing Director in Equity Capital Markets at UBS and Credit Suisse, with postings in New York, Hong Kong, and London.
Mr. Barg previously served on the boards of Cardinal Health and Catalent. He holds an M.B.A. from the Stanford University Graduate School of Business and a B.A. from Wesleyan University. In addition, Mr. Barg was a Henry Luce Scholar in Hong Kong and a Coro Fellow in Public Affairs in New York.
About Abe Ceesay
Abe Ceesay is CEO of Rapport Therapeutics and has nearly two decades of executive and public company biopharmaceutical industry experience. Before joining Rapport, he served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics. Before joining Tiburio, Mr. Ceesay held positions including COO at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, VP of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme.
Mr. Ceesay serves on the boards of Rapport Therapeutics, Pacira BioSciences, and Life Science Cares, as well as on the Board of Trustees at The Museum of Science in Boston. He holds an M.B.A. from Suffolk University’s Sawyer School of Management and a B.A. from Ithaca College.
About Mark Enyedy
Mark Enyedy has nearly three decades of combined general management, business development, and legal experience in the biotechnology industry. He brings significant M&A and capital markets experience, as well as public healthcare board experience. He most recently served as the President and CEO of ImmunoGen from 2016 until it was acquired by AbbVie in 2024. Mr. Enyedy joined ImmunoGen from Shire plc, where he served as EVP and Head of Corporate Development, leading the company’s strategy, M&A, and corporate planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corporation in diverse roles, most recently as President of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.
Mark Enyedy serves on the boards of BioMarin and Ergomed plc, and previously served on the boards of ImmunoGen, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals, as well as The American Cancer Society of Eastern New England and The Biotechnology Innovation Organization. Mr. Enyedy holds a J.D. from Harvard Law School and a B.S. from Northeastern University.
About Paul Graves
Paul Graves is CEO of Rio Tinto Lithium (previously Arcadium Lithium until it was acquired by Rio Tinto in March 2025) and brings significant executive leadership and public company board experience, as well as investment banking and M&A expertise. Previously, Mr. Graves served as CEO of Livent and was an integral part of the merger with Allkem that created Arcadium Lithium. Previously, Mr. Graves was EVP and CFO of FMC Corporation. Before joining FMC, he was a partner at Goldman Sachs, serving in a variety of roles, including as Head of Natural Resources for Asia and Global Head of Chemical Investment Banking.
Paul Graves served on the board of Arcadium Lithium until its acquisition by Rio Tinto, and also previously served on the boards of Livent and Lydall. He holds a B.A. from Nottingham Trent University.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them.
For more: https://www.criver.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.